FIELD: medicine.
SUBSTANCE: group of inventions relates to pharmaceutics and medicine and concerns a pharmaceutical product consisting of Beta2-microglobulin (β2m) or its functional version exhibiting at least 90% identity with a polypeptide sequence of human protein β2m as an active ingredient, and carrier-Liposomes, for use in pharmaceutical compositions for treating autoimmune diseases and to reduce β2m deficiency in membrane systems MHC-I.
EFFECT: group of inventions provides ability to recover normal ratio of NS/β2m in membrane systems MHC-I in a patient.
20 cl, 1 tbl, 3 ex, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| GENETICALLY MODIFIED MHISTOCOMPATIBILITY COMPLEX MICE | 2012 |
|
RU2783984C2 |
| GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE | 2012 |
|
RU2653433C2 |
| GENETICALLY MODIFIED ANIMALS OTHER THAN HUMANS FOR PRODUCING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS FOR PRODUCTION AND VERSIONS OF USE THEREOF | 2019 |
|
RU2819525C2 |
| LIPOSOMES CONTAINING OLIGOPEPTIDES - FRAGMENTS OF MYELIN BASIC PROTEIN, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING MULTIPLE SCLEROSIS | 2009 |
|
RU2448685C2 |
| STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE | 2016 |
|
RU2754041C2 |
| METHODS FOR TREATMENT OF AUTOIMMUNE DISEASE USING ALLOGENIC T-CELLS | 2017 |
|
RU2773831C2 |
| RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2790447C2 |
| MTB-C VACCINE AGAINST ASTHMA | 2012 |
|
RU2602771C2 |
| METHOD FOR TREATING INFECTION CAUSED WITH HUMAN PAPILLOMA VIRUS (HPV) | 2001 |
|
RU2282461C2 |
| MODIFIED EPITOPES FOR AMPLIFYING RESPONSES OF CD4+ T-CELLS | 2013 |
|
RU2724994C2 |
